Cargando…

Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer

BACKGROUND: The tumour microenvironment (TME) not only plays a role during tumour progression and metastasis but also profoundly influences treatment efficacy. Environment-mediated drug resistance is a result of crosstalk between tumour cells and stroma. The presence of a “stromal exhaustion” respon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lyu, Xintong, Wang, Ping, Qiao, Qiao, Jiang, Yuanjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166145/ https://www.ncbi.nlm.nih.gov/pubmed/34059019 http://dx.doi.org/10.1186/s12885-021-08350-1

Ejemplares similares

PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection
por: Lyu, Xintong, et al.
Publicado: (2019)

Identification of an immune classification for cervical cancer and integrative analysis of multiomics data
por: Lyu, Xintong, et al.
Publicado: (2021)

Gene signatures based on therapy responsiveness provide guidance for combined radiotherapy and chemotherapy for lower grade glioma
por: Li, Guangqi, et al.
Publicado: (2020)

The Prognostic and Therapeutic Value of PD-L1 in Glioma
por: Chen, Ruo Qiao, et al.
Publicado: (2019)

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
por: Jiang, Xianjie, et al.
Publicado: (2019)

Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies
por: Liu, Jiaxing, et al.
Publicado: (2022)

Identification of aberrantly methylated differentially expressed genes in glioblastoma multiforme and their association with patient survival
por: Zhang, Miao, et al.
Publicado: (2019)

Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke
por: Bodhankar, Sheetal, et al.
Publicado: (2014)

Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis
por: Duchnowska, Renata, et al.
Publicado: (2016)

Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment
por: Koyama, Shohei, et al.
Publicado: (2018)

Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
por: Wang, Yusha, et al.
Publicado: (2022)

Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
por: Koirala, Pratistha, et al.
Publicado: (2016)

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
por: Morsch, Ronja, et al.
Publicado: (2020)

Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
por: Zhou, Kaijian, et al.
Publicado: (2020)

The role of surgery on the primary tumor site in bladder cancer with distant metastasis: significance of histology type and metastatic pattern
por: Wang, Ping, et al.
Publicado: (2020)

Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test
por: Yuan, Keyu, et al.
Publicado: (2022)

Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma
por: Lin, Hansen, et al.
Publicado: (2023)

Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications
por: Zhu, Tianyi, et al.
Publicado: (2022)

Modifying the Non-muscle Invasive Bladder Cancer Immune Microenvironment for Optimal Therapeutic Response
por: Annels, Nicola E., et al.
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2019)

Regulation of PD-L1 expression in the tumor microenvironment
por: Yi, Ming, et al.
Publicado: (2021)

In silico analysis of the immune microenvironment in bladder cancer
por: Zhang, Ye, et al.
Publicado: (2020)

Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers
por: Prodeus, Aaron, et al.
Publicado: (2015)

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
por: Jung, Max, et al.
Publicado: (2023)

The role of lipid metabolism in tumor immune microenvironment and potential therapeutic strategies
por: Wang, Danting, et al.
Publicado: (2022)

Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies
por: Ying, Hui, et al.
Publicado: (2023)

PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments
por: Valentini, Anna Maria, et al.
Publicado: (2018)

PD-L1-related IncRNAs are associated with malignant characteristics and immune microenvironment in glioma
por: Xia, Zhiwei, et al.
Publicado: (2023)

Expression and clinical significance of PD-L1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment
por: Quan, Qiuying, et al.
Publicado: (2023)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
por: He, Jiabei, et al.
Publicado: (2015)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
por: Wang, Man, et al.
Publicado: (2023)

A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer
por: Liu, Zhi, et al.
Publicado: (2021)

Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment
por: Wang, Rui-Bin, et al.
Publicado: (2020)

Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer
por: Yan, Yilin, et al.
Publicado: (2020)

Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma
por: Strait, Alexander A., et al.
Publicado: (2021)

Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses
por: Li, YaFei, et al.
Publicado: (2023)

Identification and Mechanism of the PD-1/PD-L1 Genomic Signature SORL1 as Protective Factor in Bladder Cancer
por: Xu, Yajing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2v91fno4c29npdc5i04r15nma1